Technology
Health
Pharmaceutical

Revance Therapeutics

$11.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.86 (-6.76%) Today
$0.00 (0.00%) As of 4:28 PM EDT after-hours

Why Robinhood?

You can buy or sell RVNC and other stocks, options, ETFs, and crypto commission-free!

About RVNC

Revance Therapeutics, Inc. Common Stock, also called Revance Therapeutics, is a clinical stage biotechnology company. Read More It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.

Employees
170
Headquarters
Newark, California
Founded
1999
Market Cap
559.74M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
376.33K
High Today
$12.84
Low Today
$11.81
Open Price
$12.75
Volume
412.68K
52 Week High
$30.60
52 Week Low
$10.37

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biotechnology
Manufacturing
2014 IPO

RVNC Earnings

-$1.12
-$0.98
-$0.85
-$0.71
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.